Langner Cord, von Wasielewski Reinhard, Ratschek Manfred, Rehak Peter, Zigeuner Richard
Institute of Pathology, University of Graz Medical School, Graz, Austria.
Urology. 2004 Sep;64(3):611-6. doi: 10.1016/j.urology.2004.04.072.
To analyze p27 and S-phase kinase-associated protein 2 (Skp2) expression in upper urinary tract transitional cell carcinoma (TCC) with respect to biologic significance. p27 (p27/kip1) is involved in cell cycle control, and loss of p27 protein expression may result in tumor development and/or progression. The association of p27 with the ubiquitin ligase subunit Skp2 targets p27 for degradation.
A total of 53 upper urinary tract TCC specimens were investigated immunohistochemically using a tissue microarray technique. The immunoreactivity of p27 and Skp2 was analyzed with respect to associations with pT stage, grade, and prognosis.
Non-neoplastic renal tissue showed p27 immunoreactivity in tubule epithelium and pelvic urothelium, but lacked immunoreactivity for Skp2. In the TCC specimens, p27 immunoreactivity was noted in 47 (89%) of 53 cases. High p27 expression (50% or greater of tumor cell nuclei) tended to decrease with rising tumor stage (14 [45%] of 31 with pT1-pT2 versus 4 [18%] of 22 with pT3; P = 0.076), but was independent of tumor grade (11 [39%] of 28 grade 2 versus 7 [28%] of 25 grade 3-4; P = 0.56). Skp2 immunoreactivity was noted in 32 (60%) of 53 tumors. Skp2 expression increased with rising tumor stage (9 [41%] of 22 pT1 versus 23 [74%] of 31 pT2-pT3; P = 0.023) and tumor grade (12 [43%] of 28 grade 2 versus 20 [80%] of 25 grade 3; P = 0.043) and was associated with angioinvasion (P = 0.017). In multivariate analysis, tumor stage proved to be the only independent prognostic factor regarding disease-free survival.
p27 and Skp2 are additional biomarkers in urogenital pathologic findings. The statistically significant association of Skp2 expression with high-grade TCC, as well as the lack of expression in non-neoplastic tissue, suggests that Skp2 could be a promising target for future cancer therapy strategies.
分析p27和S期激酶相关蛋白2(Skp2)在上尿路移行细胞癌(TCC)中的表达及其生物学意义。p27(p27/kip1)参与细胞周期调控,p27蛋白表达缺失可能导致肿瘤发生和/或进展。p27与泛素连接酶亚基Skp2的结合会促使p27降解。
采用组织芯片技术对53例上尿路TCC标本进行免疫组织化学研究。分析p27和Skp2的免疫反应性与pT分期、分级及预后的相关性。
非肿瘤性肾组织在肾小管上皮和肾盂尿路上皮显示p27免疫反应性,但缺乏Skp2免疫反应性。在TCC标本中,53例中有47例(89%)显示p27免疫反应性。p27高表达(肿瘤细胞核的50%或更多)倾向于随肿瘤分期升高而降低(pT1 - pT2的31例中有14例[45%],pT3的22例中有4例[18%];P = 0.076),但与肿瘤分级无关(2级的28例中有11例[39%],3 - 4级的25例中有7例[28%];P = 0.56)。53例肿瘤中有32例(60%)显示Skp2免疫反应性。Skp2表达随肿瘤分期升高而增加(pT1的22例中有9例[41%],pT2 - pT3的31例中有23例[74%];P = 0.023),也随肿瘤分级升高而增加(2级的28例中有12例[43%],3级的25例中有20例[80%];P = 0.043),并且与血管侵犯相关(P = 0.017)。多因素分析显示,肿瘤分期是无病生存的唯一独立预后因素。
p27和Skp2是泌尿生殖系统病理检查中的额外生物标志物。Skp2表达与高级别TCC的统计学显著相关性,以及在非肿瘤组织中的缺乏表达,表明Skp2可能是未来癌症治疗策略的一个有前景的靶点。